STAAR Surgical (NASDAQ:STAA) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Friday.
Separately, Zacks Investment Research downgraded shares of STAAR Surgical from a “hold” rating to a “sell” rating in a research note on Wednesday, March 14th. One research analyst has rated the stock with a sell rating and three have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $17.67.
STAAR Surgical (STAA) opened at $16.05 on Friday. The stock has a market cap of $673.04, a price-to-earnings ratio of -401.25 and a beta of 1.22. STAAR Surgical has a 52 week low of $8.95 and a 52 week high of $17.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.13 and a current ratio of 2.82.
STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings results on Wednesday, February 28th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.03 by ($0.01). The business had revenue of $24.85 million for the quarter. STAAR Surgical had a negative net margin of 2.36% and a negative return on equity of 2.28%. sell-side analysts forecast that STAAR Surgical will post 0.1 EPS for the current fiscal year.
In other news, insider Samuel J. Gesten sold 2,833 shares of the firm’s stock in a transaction on Thursday, March 22nd. The shares were sold at an average price of $16.05, for a total transaction of $45,469.65. Following the completion of the transaction, the insider now owns 38,316 shares of the company’s stock, valued at $614,971.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Caren L. Mason sold 6,667 shares of the firm’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $16.09, for a total transaction of $107,272.03. Following the transaction, the chief executive officer now directly owns 51,513 shares of the company’s stock, valued at approximately $828,844.17. The disclosure for this sale can be found here. Insiders have sold 13,479 shares of company stock valued at $216,561 in the last ninety days. Insiders own 3.40% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. Prudential Financial Inc. acquired a new stake in shares of STAAR Surgical during the third quarter worth $138,000. Citadel Advisors LLC acquired a new stake in shares of STAAR Surgical during the third quarter worth $172,000. Macquarie Group Ltd. increased its position in shares of STAAR Surgical by 138.2% during the fourth quarter. Macquarie Group Ltd. now owns 17,630 shares of the medical instruments supplier’s stock worth $273,000 after buying an additional 10,230 shares during the period. Driehaus Capital Management LLC acquired a new stake in shares of STAAR Surgical during the fourth quarter worth $292,000. Finally, MetLife Investment Advisors LLC acquired a new stake in shares of STAAR Surgical during the fourth quarter worth $301,000. 78.95% of the stock is owned by hedge funds and other institutional investors.
STAAR Surgical Company Profile
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.